Novan’s macromolecular system for delivering nitric oxide.
New data on Novan’s experimental acne gel, SB204, suggests the product works quickly and safely without increasing the risk of antibiotic resistance.
SB204’s active ingredient, NVN1000, is a new molecular entity which has immunomodulatory and antimicrobial activity and inhibits lipogenesis.
The research was presented at the 2014 Annual Meeting of the Society for Investigative Dermatology in Albuquerque, New Mexico. In the Phase 2 study, 153 subjects were randomized to receive twice daily topical applications of SB204 1%, SB204 4%, or vehicle gel for 12 weeks.
At 12 weeks, individuals in the 4% arm showed a greater reduction in inflammatory lesions than those in the control arm. Participants in the 1% and 4% groups had a reduction in non-inflammatory lesion counts from baseline, compared with those in the control arm. These changes were seen as early as 4 weeks of treatment. In addition, individuals treated with the new gel had 80% less sebum on the skin’s surface than those who were randomized to receive placebo.
The new treatment had a similar safety profile as the vehicle gel.
